Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Syndax Pharmaceuticals stock

SNDX
US87164F1057
A2AFL6

Price

14.29
Today +/-
-0.18
Today %
-1.32 %

Syndax Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Syndax Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Syndax Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Syndax Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Syndax Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Syndax Pharmaceuticals Stock Price History

DateSyndax Pharmaceuticals Price
3/5/202514.29 undefined
3/4/202514.48 undefined
3/3/202514.38 undefined
3/2/202515.48 undefined
2/27/202515.64 undefined
2/26/202515.28 undefined
2/25/202515.57 undefined
2/24/202515.24 undefined
2/23/202515.67 undefined
2/20/202516.38 undefined
2/19/202515.99 undefined
2/18/202514.75 undefined
2/17/202514.62 undefined
2/13/202514.92 undefined
2/12/202515.08 undefined
2/11/202514.86 undefined
2/10/202515.01 undefined
2/9/202515.13 undefined
2/6/202515.52 undefined
2/5/202515.82 undefined

Syndax Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Syndax Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Syndax Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Syndax Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Syndax Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Syndax Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Syndax Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Syndax Pharmaceuticals’s growth potential.

Syndax Pharmaceuticals Revenue, EBIT and net profit per share

DateSyndax Pharmaceuticals RevenueSyndax Pharmaceuticals EBITSyndax Pharmaceuticals Net Income
2030e870.49 M undefined0 undefined214.71 M undefined
2029e662.18 M undefined118.32 M undefined96.3 M undefined
2028e571.55 M undefined13.67 M undefined6.27 M undefined
2027e387.58 M undefined-141.5 M undefined-134.52 M undefined
2026e204.58 M undefined-277.93 M undefined-263.54 M undefined
2025e88.77 M undefined-372.86 M undefined-339.77 M undefined
2024e98.47 M undefined-280.23 M undefined-277.08 M undefined
20230 undefined-229.95 M undefined-209.36 M undefined
20220 undefined-151.8 M undefined-149.3 M undefined
2021139.7 M undefined26.2 M undefined24.9 M undefined
20201.5 M undefined-71.4 M undefined-77.1 M undefined
20191.5 M undefined-57.5 M undefined-56 M undefined
20181.5 M undefined-75.9 M undefined-74 M undefined
20172.1 M undefined-62 M undefined-60.8 M undefined
20161.2 M undefined-43.8 M undefined-47.1 M undefined
2015600,000 undefined-20.5 M undefined-103.8 M undefined
20140 undefined-21.3 M undefined-26.4 M undefined
20130 undefined-8.6 M undefined-60.5 M undefined
20120 undefined-8.8 M undefined-9.9 M undefined
20110 undefined-9.6 M undefined-13.1 M undefined

Syndax Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
0000012111139009888204387571662870
------100.00-50.00--13,800.00----10.20131.8289.7147.5515.9431.42
--------------------
00000000000000000000
-13-9-60-26-103-47-60-74-56-7724-149-209-277-339-263-134696214
--30.77566.67-56.67296.15-54.3727.6623.33-24.3237.50-131.17-720.8340.2732.5422.38-22.42-49.05-104.481,500.00122.92
17.417.417.417.417.414.62125.430.541.353.660.870.370000000
--------------------
Details

Keystats

ⓘ

Revenue and Growth

The Syndax Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Syndax Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
4.20.614.312.287.3107131.381.661.1297.7446.8484.4577.58
0000000000000
0000000000000
0000000000000
0.20.10.30.30.81.21.81.51.20.91.11.32.07
4.40.714.612.588.1108.2133.183.162.3298.6447.9485.7579.65
0.10000.10.30.30.410.51.31.11.5
0000003.200005.529.83
0000000000000
0000000000000
0000000000000
0.30.82.50.31.80.20.20.20.21.300.90.68
0.40.82.50.31.90.53.70.61.21.81.37.532
4.81.517.112.890108.7136.883.763.5300.4449.2493.2611.65
                         
4949147.6154.1326.300000000.01
000000.390.470.490.530.820.951.161.46
-68.9-78.8-135.7-159.8-259.7-305.3-366.1-439.4-495.5-568.6-543.7-693-902.4
00000100-1000000-800218
0000000000000
-19.1-28.711.9-5.766.684.2104.453.131.6252.2408.3467.5554.2
0.80.81.10.41.52.42.21.46.23.55.74.49.96
1.92.71.73.52.26.81213.110.711.614.824.740.89
2.90.3001.21.21.61.51.51.50.207.23
0000000000000
7.821.306.4000002.3000.01
13.425.12.810.34.910.415.81618.418.920.729.158.1
6.2007.40000017.819.900.01
0000000000000
4.35.12.50.818.414.517.114.813.611.70.70.70.58
10.55.12.58.218.414.517.114.813.629.520.60.70.59
23.930.25.318.523.324.932.930.83248.441.329.858.68
4.81.517.212.889.9109.1137.383.963.6300.6449.6497.3612.88
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Syndax Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Syndax Pharmaceuticals's financial health and stability.

Assets

Syndax Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Syndax Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Syndax Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Syndax Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-13-9-14-19-24-44-60-73-56-7324-149-209
0000000000000
0000000000000
0000142700-7-9131
2087101111111118272947
0000000001220
0000000000000
-10-9-7-14-2-35-47-68-50-7129-133-160
0000000000000
20-41-61-18-175112-142-40-186117
20-31-61-18-165112-142-40-186117
0000000000000
86-314-90000190-210
00260875427152828493193264
8520127754751528304118172264
00-1-1-10480002500
0000000000000
0-39013011-1-990106-147221
-10.03-9.29-7.34-14.39-2.48-35.42-47.45-68.72-50.61-71.2629-133.68-160.6
0000000000000

Syndax Pharmaceuticals stock margins

The Syndax Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Syndax Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Syndax Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Syndax Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Syndax Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Syndax Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Syndax Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Syndax Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Syndax Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Syndax Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Syndax Pharmaceuticals Margin History

Syndax Pharmaceuticals Gross marginSyndax Pharmaceuticals Profit marginSyndax Pharmaceuticals EBIT marginSyndax Pharmaceuticals Profit margin
2030e0 %0 %24.67 %
2029e0 %17.87 %14.54 %
2028e0 %2.39 %1.1 %
2027e0 %-36.51 %-34.71 %
2026e0 %-135.85 %-128.82 %
2025e0 %-420.03 %-382.77 %
2024e0 %-284.58 %-281.37 %
20230 %0 %0 %
20220 %0 %0 %
20210 %18.75 %17.82 %
20200 %-4,760 %-5,140 %
20190 %-3,833.33 %-3,733.33 %
20180 %-5,060 %-4,933.33 %
20170 %-2,952.38 %-2,895.24 %
20160 %-3,650 %-3,925 %
20150 %-3,416.67 %-17,300 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %

Syndax Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Syndax Pharmaceuticals earnings per share therefore indicates how much revenue Syndax Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Syndax Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Syndax Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Syndax Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Syndax Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Syndax Pharmaceuticals Revenue, EBIT and net profit per share

DateSyndax Pharmaceuticals Sales per ShareSyndax Pharmaceuticals EBIT per shareSyndax Pharmaceuticals Earnings per Share
2030e10.2 undefined0 undefined2.52 undefined
2029e7.76 undefined0 undefined1.13 undefined
2028e6.7 undefined0 undefined0.07 undefined
2027e4.54 undefined0 undefined-1.58 undefined
2026e2.4 undefined0 undefined-3.09 undefined
2025e1.04 undefined0 undefined-3.98 undefined
2024e1.15 undefined0 undefined-3.25 undefined
20230 undefined-3.27 undefined-2.98 undefined
20220 undefined-2.5 undefined-2.46 undefined
20212.61 undefined0.49 undefined0.46 undefined
20200.04 undefined-1.73 undefined-1.87 undefined
20190.05 undefined-1.89 undefined-1.84 undefined
20180.06 undefined-2.99 undefined-2.91 undefined
20170.1 undefined-2.95 undefined-2.9 undefined
20160.08 undefined-3 undefined-3.23 undefined
20150.03 undefined-1.18 undefined-5.97 undefined
20140 undefined-1.22 undefined-1.52 undefined
20130 undefined-0.49 undefined-3.48 undefined
20120 undefined-0.51 undefined-0.57 undefined
20110 undefined-0.55 undefined-0.75 undefined

Syndax Pharmaceuticals business model

Syndax Pharmaceuticals Inc. is a biotechnology company based in Waltham, Massachusetts that focuses on the development of novel therapeutics for cancer and immune disorders. The company was founded in 2005 by Arlene Morris and has been listed on NASDAQ since 2014. Business model and product pipeline: Syndax develops small molecules that are capable of modulating epigenetic changes in cells. This approach is based on the understanding that cancer cells often have genetic alterations that result in changes in gene expression. By modulating such epigenetic changes, cancer cells can function normally again, which can help stop or inhibit the growth of cancer cells. The company's product pipeline includes several drugs that are being developed in various stages of clinical research. One of the most advanced programs is E2112, an orally administered drug targeting breast cancer. The drug is currently in Phase III studies that are investigating the efficacy and safety of the drug in combination with other standard therapies. Another promising program is SNDX-6352, an anti-CSF-1 receptor antibody being developed for the treatment of various types of cancer, including certain solid tumors and hematologic malignancies. The drug has been successfully tested in Phase Ib studies, and the company is currently planning to evaluate it in further clinical trials. In addition to cancer research, Syndax is also working on the development of therapeutics for various inflammatory and immunologic diseases. The company is working on a program for the treatment of idiopathic pulmonary fibrosis and also a program for the treatment of thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. In addition to internally developed drugs, the company is collaborating with other biotechnology and pharmaceutical companies to explore innovative treatment options for other diseases. The company has entered into a partnership with Japanese company Kyowa Hakko Kirin Co. Ltd. to develop and market the SNDX-6352 program. Current developments: Syndax has recently experienced strong growth and is investing significantly in research and development to expand its pipeline and expand its drugs. The company recently completed a financing round that raised $80 million to advance its development projects. A key milestone for the company was the appointment of Briggs W. Morrison as CEO in 2020. Morrison, an experienced pharmaceutical manager, was previously the Chief Executive Officer and President of Syndax until 2016. He is now returning to the company and leading efforts to develop innovative therapeutics. Morrison has previously worked at Pfizer and AstraZeneca, bringing valuable experience in the development and marketing of new drugs. Summary: Syndax Pharmaceuticals Inc. is a biotechnology company that focuses on the development of drugs for cancer and inflammatory diseases. The company has a promising product pipeline that includes several therapeutics in various stages of development, including E2112 and SNDX-6352. Syndax recently completed a strong financing round and plans to continue its research and development efforts to discover and develop new innovative therapeutics. Syndax Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Syndax Pharmaceuticals SWOT Analysis

Strengths

Syndax Pharmaceuticals Inc has several key strengths that contribute to its success in the pharmaceutical industry.

  • Strong product pipeline with potential breakthrough therapies
  • Experienced and knowledgeable research and development team
  • Established partnerships with leading healthcare organizations
  • Effective marketing strategies for product promotion and awareness
  • Well-established distribution networks in key markets

Weaknesses

Despite its strengths, Syndax Pharmaceuticals Inc also faces certain weaknesses that need to be addressed.

  • Limited financial resources for expansion and research
  • Dependence on a few key products for revenue generation
  • Stiff competition from larger pharmaceutical companies
  • Challenges in gaining regulatory approvals for new drug candidates
  • Risk of potential side effects associated with certain therapies

Opportunities

Syndax Pharmaceuticals Inc can explore various opportunities in the marketplace to achieve growth and success.

  • Increasing demand for innovative therapeutics for various diseases
  • Emerging markets with untapped potential for expansion
  • Advancements in technology that enhance drug discovery and development
  • Potential collaborations with research institutions and academic centers
  • Growing emphasis on personalized medicine and targeted therapies

Threats

Syndax Pharmaceuticals Inc faces certain threats that could impact its business operations and growth.

  • Stringent government regulations and increasing compliance requirements
  • Rapidly changing market dynamics and evolving customer preferences
  • Potential lawsuits or legal challenges related to product safety or efficacy
  • Intellectual property infringement by competitors
  • Global economic uncertainties affecting healthcare spending and investments
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Syndax Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Syndax Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Syndax Pharmaceuticals shares outstanding

The number of shares was Syndax Pharmaceuticals in 2024 — This indicates how many shares 70.371 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Syndax Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Syndax Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Syndax Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Syndax Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Syndax Pharmaceuticals.

Syndax Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2024-0.25 -1.1  (-348.07 %)2024 Q4
9/30/2024-1.14 -0.98  (13.67 %)2024 Q3
6/30/2024-0.93 -0.8  (14.2 %)2024 Q2
3/31/2024-1 -0.85  (14.84 %)2024 Q1
12/31/2023-1.01 -1  (1.39 %)2023 Q4
9/30/2023-0.81 -0.73  (10.03 %)2023 Q3
6/30/2023-0.75 -0.64  (14.31 %)2023 Q2
3/31/2023-0.61 -0.59  (2.9 %)2023 Q1
12/31/2022-0.66 -0.62  (6.3 %)2022 Q4
9/30/2022-0.65 -0.58  (10.45 %)2022 Q3
1
2
3
4

Eulerpool ESG Scorecard© for the Syndax Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

76/ 100

🌱 Environment

82

👫 Social

84

🏛️ Governance

63

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees62
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Syndax Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
9.98126 % Kynam Capital Management LP8,520,0002,677,07512/31/2024
8.64038 % BlackRock Institutional Trust Company, N.A.7,375,432594,29212/31/2024
6.49172 % Goldman Sachs & Company, Inc.5,541,3294,289,77512/31/2024
5.76926 % Morgan Stanley & Co. LLC4,924,6414,343,03712/31/2024
5.70174 % The Vanguard Group, Inc.4,867,003-5,00612/31/2024
4.96070 % Wellington Management Company, LLP4,234,455-751,52112/31/2024
4.58940 % State Street Global Advisors (US)3,917,516146,69012/31/2024
3.36528 % StemPoint Capital LP2,872,6011,141,41012/31/2024
2.91940 % Soleus Capital Management, L.P.2,492,0001,401,01612/31/2024
2.66518 % Avoro Capital Advisors LLC2,275,000-1,613,43712/31/2024
1
2
3
4
5
...
10

Syndax Pharmaceuticals Executives and Management Board

Mr. Michael Metzger

(52)
Syndax Pharmaceuticals Chief Executive Officer, Director (since 2015)
Compensation 4.11 M

Mr. Steve Sabus

(57)
Syndax Pharmaceuticals Chief Commercial Officer
Compensation 3.92 M

Mr. Keith Goldan

(51)
Syndax Pharmaceuticals Chief Financial Officer, Principal Accounting Officer, Treasurer
Compensation 2.99 M

Dr. Catherine Madigan

(51)
Syndax Pharmaceuticals Chief Medical Officer
Compensation 2.64 M

Dr. Briggs Morrison

(64)
Syndax Pharmaceuticals Director (since 2015)
Compensation 2.37 M
1
2
3

Most common questions regarding Syndax Pharmaceuticals

What values and corporate philosophy does Syndax Pharmaceuticals represent?

Syndax Pharmaceuticals Inc represents a strong set of values and corporate philosophy. The company is dedicated to developing innovative therapies that can improve the lives of patients. Syndax strongly believes in collaboration, fostering partnerships to advance their mission. With a commitment to scientific excellence and integrity, Syndax aims to deliver cutting-edge solutions in oncology and other therapeutic areas. By combining their expertise with strategic collaborations, Syndax Pharmaceuticals Inc strives to make a significant impact in the field of healthcare and provide hope for patients worldwide.

In which countries and regions is Syndax Pharmaceuticals primarily present?

Syndax Pharmaceuticals Inc is primarily present in the United States. As a biopharmaceutical company headquartered in Waltham, Massachusetts, Syndax focuses on developing innovative therapies for the treatment of cancer. With a strong presence in the U.S., Syndax Pharmaceuticals Inc is committed to advancing its pipeline and collaborating with key industry stakeholders to bring potential breakthrough treatments to patients in need.

What significant milestones has the company Syndax Pharmaceuticals achieved?

Syndax Pharmaceuticals Inc has achieved several significant milestones in its journey. One of the notable achievements is the successful clinical development of their lead product candidate, entinostat. This drug has shown promising results in treating various types of cancer, particularly advanced breast cancer. Additionally, Syndax Pharmaceuticals has made substantial progress in obtaining regulatory approvals and has initiated collaborations with renowned research institutions and pharmaceutical companies. Overall, Syndax Pharmaceuticals Inc has demonstrated its commitment to innovation and growth in the field of oncology through these remarkable milestones.

What is the history and background of the company Syndax Pharmaceuticals?

Syndax Pharmaceuticals Inc is a biopharmaceutical company with a rich history and background. Founded in 2005, Syndax is dedicated to developing therapies for various cancers. The company has made significant progress in the field of epigenetics, focusing on targeted therapies and innovative drug development. Syndax's commitment to improving patient outcomes and addressing unmet medical needs has driven its success in the industry. With a dedicated team of scientists and researchers, Syndax continues to advance its portfolio of novel therapeutics, providing hope to patients worldwide. This dedication to innovative solutions for cancer treatment has made Syndax Pharmaceuticals Inc a prominent player in the healthcare sector.

Who are the main competitors of Syndax Pharmaceuticals in the market?

The main competitors of Syndax Pharmaceuticals Inc in the market include companies such as Merck & Co. Inc., Bristol-Myers Squibb Company, Roche Holding AG, Pfizer Inc., and Novartis AG.

In which industries is Syndax Pharmaceuticals primarily active?

Syndax Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Syndax Pharmaceuticals?

The business model of Syndax Pharmaceuticals Inc. revolves around developing and commercializing novel medicines to treat cancer and other diseases. As a biopharmaceutical company, Syndax focuses on developing therapies that target the epigenetic regulation of gene expression, aiming to improve patient outcomes. By leveraging its innovative approach and scientific expertise, Syndax seeks to discover and develop effective treatments to address unmet medical needs. With a focus on precision medicine and personalized therapies, Syndax is committed to advancing the field of medicine and improving the lives of patients worldwide.

What is the P/E ratio of Syndax Pharmaceuticals 2025?

The Syndax Pharmaceuticals P/E ratio is -2.96.

What is the P/S ratio of Syndax Pharmaceuticals 2025?

The Syndax Pharmaceuticals P/S ratio is 11.33.

What is the Quality Investing of Syndax Pharmaceuticals?

The Quality Investing for Syndax Pharmaceuticals is 3/10.

What is the revenue of Syndax Pharmaceuticals 2025?

The expected Syndax Pharmaceuticals revenue is 88.77 M USD.

How high is the profit of Syndax Pharmaceuticals 2025?

The expected Syndax Pharmaceuticals profit is -339.77 M USD.

What is the business model of Syndax Pharmaceuticals

Syndax Pharmaceuticals Inc. is a biopharmaceutical company based in Waltham, Massachusetts. The company specializes in the development of therapeutics for cancer and pursues an innovative approach to improve treatment options for cancer patients. Syndax Pharmaceuticals' business model is based on several divisions and products, which will be introduced below. 1. Drug Development Syndax Pharmaceuticals focuses on the development of new therapeutics for cancer. The company works closely with leading cancer experts and clinicians to find the best approaches for cancer treatment. The company employs a combination of chemical synthesis and biological methods to develop innovative therapies targeting specific types of cancer. Currently, multiple drug candidates based on epigenetic modulation are in clinical testing at different stages of development. 2. Licensing Syndax Pharmaceuticals also licenses patents and trademarks from other biopharmaceutical companies to expand its product range. The company has established several partnerships with leading companies in the field of oncology, including Merck & Co. and Kyowa Hakko Kirin. Through licensing and collaborations, Syndax Pharmaceuticals can achieve faster and more effective development of new drugs. 3. Product Distribution Syndax Pharmaceuticals utilizes strategic partnerships and distribution channels to place its products in the market. Currently, the company distributes the drug Entinostat, which is in phase III clinical testing. The medication is used in combination with other chemotherapeutics to enhance treatment effectiveness in breast and lung cancer patients. Syndax Pharmaceuticals aims to obtain approval for Entinostat for other types of cancer as well. 4. Intellectual Property Licensing Another important business area for Syndax Pharmaceuticals is the licensing of intellectual property to other companies. The company possesses one of the most comprehensive patent platforms in the field of cancer therapy, including several patents on the combination of Entinostat with other active substances. The strategic focus on IP licensing allows the company to generate additional revenue. In summary, Syndax Pharmaceuticals' business model is based on the development of innovative cancer medications. The company pursues an interdisciplinary approach and collaborates closely with experts and clinicians to maximize treatment efficacy. Through targeted licensing of intellectual property and partnerships with other companies, Syndax Pharmaceuticals advances the development of new therapeutics and contributes to improving treatment options for cancer patients.

What is the Syndax Pharmaceuticals dividend?

Syndax Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Syndax Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Syndax Pharmaceuticals or the company does not pay out a dividend.

What is the Syndax Pharmaceuticals ISIN?

The ISIN of Syndax Pharmaceuticals is US87164F1057.

What is the Syndax Pharmaceuticals WKN?

The WKN of Syndax Pharmaceuticals is A2AFL6.

What is the Syndax Pharmaceuticals ticker?

The ticker of Syndax Pharmaceuticals is SNDX.

How much dividend does Syndax Pharmaceuticals pay?

Over the past 12 months, Syndax Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Syndax Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Syndax Pharmaceuticals?

The current dividend yield of Syndax Pharmaceuticals is .

When does Syndax Pharmaceuticals pay dividends?

Syndax Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Syndax Pharmaceuticals?

Syndax Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Syndax Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Syndax Pharmaceuticals located?

Syndax Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Syndax Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Syndax Pharmaceuticals from 3/7/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/7/2025.

When did Syndax Pharmaceuticals pay the last dividend?

The last dividend was paid out on 3/7/2025.

What was the dividend of Syndax Pharmaceuticals in the year 2024?

In the year 2024, Syndax Pharmaceuticals distributed 0 USD as dividends.

In which currency does Syndax Pharmaceuticals pay out the dividend?

The dividends of Syndax Pharmaceuticals are distributed in USD.

All fundamentals about Syndax Pharmaceuticals

Our stock analysis for Syndax Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Syndax Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.